Clinical trials: Weight Changes, Body
Overweight and Obesity
Safety and Efficacy of Glucosanol in Reducing Body Weight in Overweight and Obese Subjects
Glucosanol™, the medical device to be investigated contains a proprietary plant extract that is a natural inhibitor of alpha-amylase and can reduce starch digestion.
- Trial name
- NCT01407393
- Testing
- Glucosanol
- Where
- Germany
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Overweight and Obesity, Body Weight Changes
Microalgae Extract Phaeosol Combined to Exercise in Healthy Overweight Women : Efficacy on Body Weight Management
PhaoeSOL (Microphyt, Baillargues, France) is a microalgae-based nutritional ingredient developed with a patented production process that has New Dietary Ingredient (NDI) status from the FDA (#1120).
- Conditions
- Overweight and Obesity, Body Weight Changes, Healthy Lifestyle, Exercise
- Trial name
- PHAEOSOL-ONE (NCT04761406)
- Testing
- Phaeosol group
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Microphyt
Obesity, Overweight
A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program
The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in treating obesity and leads to greater weight loss when given with a group lifestyle modification program…
- Trial name
- NCT00456521
- Testing
- Naltrexone SR 32 mg/ bupropion SR 360 mg/ day, Intensive group lifestyle modification counseling
- Where
- 9 sites in United States
- Volunteers
- 793 people
- Sponsor
- Orexigen Therapeutics, Inc
Cachexia, Anorexia
Pharmacokinetics of Megace F and Megace OS Under Fasting and Fed Conditions in Healthy Male Volunteers
Phase I study of Megace F will be conducted to investigate pharmacokinetics and safety compared to Megace OS. Phase I study divided into 3 parts written as belows.
- Trial name
- MGF (NCT01397214)
- Testing
- Megace F, Megace OS
- Where
- South Korea
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Obesity
Safety and Efficacy of APD356 in the Treatment of Obesity
This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c receptor agonist, in clinical development as a potential treatment for obesity.
- Trial name
- NCT00116740
- Testing
- APD356
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Obesity
A Controlled-Study on the Effect of a Combination of Fenofibrate and Metformin on Weight Loss and Weight Loss-Maintenance, in Obese Patients.
To investigate the effect on body weight of a combination fenofibrate and metformin on top of a moderate balanced calorie-deficit diet.
- Trial name
- NCT00349635
- Testing
- Metformin and Metformin + Fenofibrate
- Where
- 3 sites in Finland
- Volunteers
- 148 people
- Sponsor
- Solvay Pharmaceuticals
Weight Loss, Behavior, Health
Mobile Behavior Change Program for Weight Loss in Breast Cancer Survivors
The purpose of this study is to evaluate the preliminary efficacy of a Noom Breast Cancer Weight Loss Program on weight loss outcomes, quality of life, and physical activity.
- Trial name
- NCT04753268
- Testing
- Noom Healthy Weight Program
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Noom Inc.
Time Restricted Feeding
Effect of 14:10 Time-Restricted Eating on Body Weight and Metabolic Markers
The purpose of this study is to investigate the effect of engaging in time restricted eating schedule on body weight, blood glucose, and ketones (breath acetone) in individuals with obesity.
- Trial name
- NCT04492930
- Testing
- 14:10 Regimen, 12:12 Regimen
- Where
- United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Jenny Craig, Inc.
Obesity
Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMF-650 in Otherwise Healthy Overweight or Obese…
- Trial name
- NCT07223216
- Testing
- BMF-650
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Biomea Fusion Inc.
Weight Loss
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735…
- Trial name
- NCT06828055
- Testing
- VK2735
- Where
- 15 sites in United States
- Volunteers
- 280 people
- Sponsor
- Viking Therapeutics, Inc.
Obesity
A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
- Trial name
- NCT00112021
- Testing
- pramlintide acetate
- Where
- 21 sites in United States
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Obese Adults
A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities
This is a Phase 1, randomized, double-blind, placebo-controlled single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of VK3019 in overweight and obese adults without…
- Trial name
- NCT07846033
- Testing
- SC VK3019
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Viking Therapeutics, Inc.
Obesity
Efficacy Study of Betahistine on Body Weight in Obese Female Subjects
The purpose of this study is to examine the effect of betahistine on body weight in obese female subjects
- Trial name
- NCT00748436
- Testing
- betahistine dihydrochloride
- Where
- 12 sites in Belgium, Germany and 1 more
- Volunteers
- 187 people
- Sponsor
- OBEcure Ltd.
Overweight and Obesity
Web-based Weight Loss Intervention
Excess weight is a major risk factor underlying leading causes of death globally, including cardiovascular disease, type 2 diabetes, and some cancers.
- Trial name
- NCT03400696
- Testing
- Lower carbohydrate diet, Higher fiber diet, Physical activity focused
- Where
- 2 sites in United States
- Volunteers
- 63,656 people, healthy volunteers welcome
- Sponsor
- 23andMe, Inc.
Obesity
BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients.
- Trial name
- NCT00603902
- Testing
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID)
- Where
- United States
- Volunteers
- 4,008 people
- Sponsor
- Eisai Inc.
Cachexia; Cancer, Cachexia
Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
The purpose of this trial is to learn whether participants who take rilogrotug gain weight, have a better appetite, and have a better quality of life than participants who do not take rilogrotug (placebo arm).
- Conditions
- Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC)
- Trial name
- REACH (NCT07888075)
- Testing
- Rilogrotug
- Volunteers
- 950 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Obesity
A Prospective Multicenter Post Approval Study of the ReShape™ Integrated Dual Balloon System in Obese Subjects
The ReShape Post Approval Study is a prospective multicenter study of the ReShape(TM) Integrated Dual Balloon System in Obese Subjects.
- Trial name
- ReShapePAS (NCT02927665)
- Testing
- Reshape Integrated Dual Balloon
- Where
- 14 sites in United States
- Volunteers
- 186 people
- Sponsor
- ReShape Lifesciences
Obesity, Overweight
Obex, a Nutritional Supplement, in Overweight and Obese Spanish Women
The aim of the study is to evaluate the effects of a dietary supplement (Obex®) on anthropometric and physiological variables in Spanish women between 35 and 60 years who are overweight or obese.
- Trial name
- NCT01934036
- Testing
- Obex
- Where
- Spain
- Volunteers
- 92 people
- Sponsor
- Catalysis SL
Weight Loss
Study to See How Low Level Laser Light Affects Subcutaneous Fat Around the Hips and Waist
The purpose of this pilot study is to demonstrate the anatomical modulation of subcutaneous fat across the waist and hips that occurs through application of the Erchonia® ML Scanner (MLS) Laser manufactured for non-invasive body…
- Trial name
- NCT01292564
- Testing
- Erchonia MLS
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Erchonia Corporation
Non-Insulin-Dependent Diabetes Mellitus
AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes
This study compares the effects of Avandamet (rosiglitazone maleate/metformin) treatment and metformin plus sulphonylurea treatment in overweight people with type 2 diabetes.
- Trial name
- NCT00359112
- Testing
- metformin, sulphonylurea, Avandamet
- Where
- 142 sites in Belgium, France and 9 more
- Volunteers
- 544 people
- Sponsor
- GlaxoSmithKline